About Muriphys
At Muriphys, we are committed to simplifying and streamlining our pricing and ordering process. We know that time is valuable and strive to accelerate our Contact to Data process to meet our sponsors’ demanding timelines. Working with Muriphys, you can expect quick turn around, streamlined pricing, dedicated resources and constant in-study updates and communication.
GUIDING PRINCIPLES
-
Accelerate Scientific Discovery
-
Commit to Operational Excellence
-
Prioritize Employee and Partner Well-Being
-
Be a Trusted Partner to Our Customers
OUR MISSION
Muriphys' mission is to facilitate therapeutic discovery through the promotion of translational science. We pride ourselves on delivering quality, reproducible and precision focused data via operational excellence.
We prioritize our sponsors’ research objectives, budget and timelines to deliver flexible, tailored and cost effective pre-clinical research solutions in rodents.
Founders
-
Mikhael Vitenson
Founder & CEO
Mikhael Vitenson, the Co-Founder and CEO of MuriPhys, brings over 25 years of extensive experience in corporate law, having worked with several prominent law firms and multinational corporations. Mikhael shares a passion for a greener, more sustainable planet and dedicated the bulk of his career to environmental sustainability and renewable energy. In addition to his legal career, Mikhael has successfully established and managed numerous businesses across diverse industries, including food, real estate, and pet grooming. His multifaceted background combines legal acumen, passion for sustainability and entrepreneurial insight, driving Muriphys forward in its mission to deliver quality and operational excellence in the preclinical research landscape.
-
Ariel Vitenzon, Ph.D.
Founder & CSO
Ariel Vitenzon, PhD, is the Co-Founder and Chief Scientific Officer at MuriPhys LLC. Prior to establishing MuriPhys, Dr. Vitenzon held a significant role at LifeEdit Therapeutics, an Elevatebio portfolio company. There, he was instrumental in setting up a state-of-the-art facility for conducting in vivo CNS and systemic studies, and led numerous CNS-related projects. Notably, through his adept cross-functional collaboration with the LifeEdit Therapeutics and Elevatebio teams, Dr. Vitenzon propelled the company's Huntington's disease program from its nascent stages to preclinical NHP studies within a remarkable timeframe of under two years.
With over 15 years of hands-on experience in in-vivo preclinical drug development using rodent models, Dr. Vitenzon stands as a distinguished figure in his field.
Dr. Vitenzon's scholarly contributions include several papers published in peer-reviewed journals, underscoring his commitment to advancing scientific knowledge and therapeutic practices. Through Muriphys LLC, Dr. Vitenzon continues to drive forward the frontiers of preclinical research, aiming to deliver tangible advancements for the future of therapeutic interventions.
Scientific Advisory Board
-
Kamran Khodakhah, Ph.D.
Dr. Kamran Khodakhah, PhD, serves as the Chair of the Scientific Board at MuriPhys LLC, bringing an extensive and distinguished background in neuroscience. He is a prominent professor in the Dominick P. Purpura Department of Neuroscience, as well as in the departments of psychiatry and behavioral sciences, and the Saul R. Korey Department of Neurology at Albert Einstein College of Medicine. Additionally, he held the prestigious Florence and Irving Rubinstein Chair in Neuroscience. Dr. Khodakhah's contributions to the field are well-documented, with more than 50 papers published in peer-reviewed journals. His groundbreaking research continues to shape the landscape of neuroscience and offers promising directions for understanding and treating a wide array of disorders. His leadership and vision at Muriphys further reinforce the company's commitment to advancing scientific discovery and therapeutic innovation.
-
Zaven Kaprielian, Ph.D.
Dr. Zaven Kaprielian is a distinguished scientist and leader with a diverse and accomplished career spanning academia, industry, and venture capital. Dr. Kaprielian has made significant contributions to neuroscience research and therapeutic development, particularly in the areas of neurodegenerative disorders and neuropathic pain. Dr. Kaprielian served as Chief Scientific Officer at Remix Therapeutics, President & Board Member at Endlyz Therapeutics and a Venture Partner at Dementia Discovery Fund. From June 2013 to June 2018, Dr. Kaprielian was a Director of Neuroscience Research at Amgen in Cambridge, MA. In this role, he managed several teams and programs tasked with identifying novel therapeutics for neuropathic pain and neurodegenerative disorders, with a focus on ALS and Parkinson's Disease.
-
Heather Snell, Ph.D.
Dr. Heather Snell is a distinguished researcher whose wide-ranging expertise in biochemistry, pharmacology, and neuroscience has positioned her as a leading figure in her field. She focused on investigating the interactions of the GABAA ρ1 receptor with guanidine compounds—drugs known to block acid-sensing ion channels (ASICs). In January 2024, Dr. Snell established her own research program in the Neuroscience department at Yale School of Medicine as a Tenure-Track Assistant Professor. Her work at Yale represents a significant branching off from her earlier research in the cerebellum, where she continues to explore novel avenues in neurophysiology and pharmacology.
-
Brett Abrahams, Ph.D
Dr. Abrahams is a neuroscientist, geneticist, and drug hunter with experience developing therapeutics and building startups. He is the founder and President of Heppinn Biosciences, a consultancy practice launched to support venture investors and biotech companies diligence opportunities, develop drugs, and operationalize programs. He’s also an Advisory Board Member for Autism Speaks, CureShank, FAST, the POGZ Foundation and Accelerator Life Science Partners.
-
Roy Sillitoe, Ph.D.
Dr. Roy Sillitoe is an eminent neuroscientist whose research has significantly advanced our understanding of the biological bases underlying pediatric neurological diseases. With an impressive academic background and extensive postdoctoral training, Dr. Sillitoe's work has illuminated the complex neural circuitry required for proper brain function and its disruption in various neurological disorders.